APL 400-003 clinical trials
Also written APL 400-003.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 1996
How each study uses APL 400-003 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- APL 400-003
- 4
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Wyeth-Lederle Vaccines (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Apollon (1)
Studies
Open first, then newest update. How each study uses APL 400-003 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative VolunteersCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001538Written as APL 400-003How we know
- Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative VolunteersCompletedPhase 1Wyeth-Lederle VaccinesNCT00002231Written as APL 400-003How we know
- A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected PatientsCompletedPhase 1ApollonNCT00002350Written as APL 400-003How we know
- A Study of GENEVAX-HIV, a Possible VaccineCompletedPhase 1Wyeth-Lederle VaccinesNCT00002232Written as APL 400-003How we know